Welcome to our dedicated page for Evommune SEC filings (Ticker: EVMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Evommune, Inc. files regulatory documents covering its clinical-stage biotechnology business, public-company governance and capital structure. Its 8-K filings furnish operating and financial results, Regulation FD corporate presentations, material-event disclosures and clinical updates for pipeline programs including EVO756 and EVO301.
Evommune’s SEC record also includes registration materials tied to common stock offerings and proxy materials for annual meeting matters. These filings document director elections, auditor ratification, shareholder voting procedures, capital-structure disclosures, material agreements, clinical and regulatory disclosures, and risk factors associated with developing therapies for chronic inflammatory diseases.
Evommune, Inc. reported top-line results from its Phase 2b trial of oral MRGPRX2 antagonist EVO756 in moderate-to-severe chronic spontaneous urticaria. The randomized, double-blind, placebo-controlled study in 160 antihistamine-refractory patients did not meet the primary endpoint of change in Urticaria Activity Score over seven days at 12 weeks at any dose.
Based on these data, Evommune plans to cease development of EVO756 for chronic spontaneous urticaria, but will continue evaluating the drug in other indications. The company remains on track to report Phase 2b data for EVO756 in atopic dermatitis in the third quarter of 2026 and has begun a Phase 2b trial in migraine prophylaxis.
Evommune also highlighted positive Phase 2a proof-of-concept data in atopic dermatitis for its IL-18BP fusion protein EVO301, and stated it has a strong cash position supporting anticipated operations through 2028, which it believes will allow continued advancement of its inflammatory disease pipeline.
Evommune, Inc. Chief of Development Operations Janice Suzann Drew exercised stock options and sold shares in a planned trade. On June 22, 2026, she exercised options to acquire a total of 20,000 shares of common stock at exercise prices of $2.99 and $3.84 per share, then sold 20,000 shares in an open-market transaction at a weighted average price of $22.63 per share.
The filing notes that these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 9, 2026, indicating they were scheduled in advance. Footnotes also describe a standard multi-year vesting schedule for the underlying employee stock options.
Evommune, Inc. Chief Scientific Officer Jeegar Pravinkumar Patel executed an option exercise and related share sale in Evommune (EVMN) stock. On June 22, 2026, he exercised 1,488 employee stock options at $3.84 per share and sold 1,488 common shares in an open-market transaction at $22.50 per share. Following these transactions, he directly holds 46,403 shares of common stock and 27,842 employee stock options, which are scheduled to vest over time and expire on May 11, 2033. The filing notes that the trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026, indicating the timing was set in advance.
Evommune, Inc. director and President & CEO Luis C. Pena reported an open-market sale of 7,438 shares of common stock on June 22, 2026 at a weighted average price of $22.71 per share. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 2, 2026, indicating they were scheduled in advance. Following this sale, Pena directly holds 630,458 shares of Evommune common stock, so the sale represents only a small portion of his overall stake.
Evommune, Inc. director Benjamin F. McGraw III received a grant of stock options covering 15,673 shares of common stock. The options have an exercise price of $19.82 per share and expire on June 1, 2036.
According to the footnote, these options vest at the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders, provided he remains in continuous service through that date. Following this grant, he holds options to acquire 15,673 shares directly. This is a routine compensation-related award, not an open-market share purchase or sale.
Evommune, Inc. director Arthur S. Kirsch received a grant of stock options covering 15,673 shares of common stock. The options have an exercise price of $19.82 per share and expire on June 1, 2036. Following this grant, he holds options on 15,673 shares directly.
The award vests at the earlier of the first anniversary of the grant date or Evommune’s next annual meeting of stockholders, as long as Kirsch continues to serve through that vesting date. This is a compensation-related grant, not an open‑market purchase or sale.
Evommune director David E. Cohen reported both stock sales and a new option grant. He sold a total of 6,056 shares of common stock in two open-market transactions at weighted average prices of $20.21 and $21.38, executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 3, 2026.
On the same date, he received a grant of stock options covering 15,673 shares of common stock with an exercise price of $19.82 per share, expiring on June 1, 2036. These options vest at the earlier of the first anniversary of the grant date or Evommune’s next annual meeting of stockholders, as long as he continues to serve through that date.
Evommune, Inc. Chief Scientific Officer Jeegar Pravinkumar Patel reported an exercise-and-sale transaction in company stock. He exercised employee stock options to acquire 13,512 shares of common stock at a price of $3.84 per share, then sold 16,687 shares of common stock at a weighted average price of $22.74 per share in open-market transactions pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2026. Following these transactions, he directly holds 46,403 shares of common stock and 29,330 employee stock options that remain outstanding and exercisable into common stock.
Evommune, Inc. President & CEO Luis C. Pena reported an open-market sale of common stock. On June 1, 2026, he sold 16,787 shares of Evommune common stock at a weighted average price of $22.74 per share in multiple transactions. These trades were made pursuant to a pre-arranged Rule 10b5-1 trading plan. After the sale, Pena directly holds 637,896 shares of Evommune common stock.